Type
|
Public |
---|---|
Traded as | NYSE: EW S&P 500 Component |
Industry | Medical device |
Founded | 1958 (1958) |
Headquarters | Irvine, California, United States |
Key people
|
Michael A. Mussallem, Chairman & CEO |
Products | Heart valves, Critical care technology, Cardiac surgery technology |
Revenue | $2.49 billion (2015) |
Number of employees
|
8,700 |
Website | Edwards.com |
Edwards Lifesciences is an American medical equipment company specializing in artificial heart valves and hemodynamic monitoring. It is mostly known for a transcatheter aortic heart valve made of bovine tissue within a collapsible stainless-steel stent, deployed via catheter. Their SAPIEN product is an FDA-approved device for percutaneous aortic valve replacement. It is publicly traded on the NYSE under the symbol EW.
Edwards Lifesciences’ roots date to 1958, when Miles “Lowell” Edwards set out to build the first artificial heart.
Edwards was a 60-year-old, recently retired engineer holding 63 patents in an array of industries, with an entrepreneurial spirit and a dream of helping patients with heart disease. His fascination with healing the heart was sparked in his teens, when he suffered two bouts of a disease called rheumatic fever, which can scar heart valves and eventually cause the heart to fail.
With a background in hydraulics and fuel pump operations, Edwards believed the human heart could be mechanized. He presented the idea to Dr. Albert Starr, a young surgeon at the University of Oregon Medical School, who thought the idea was too complex. Instead, Starr encouraged Edwards to focus first on developing an artificial heart valve, for which there was an immediate need.
After just two years, the first Starr-Edwards mitral valve was designed, developed, tested, and successfully placed in a patient. Newspapers around the world reported on what they termed a “miraculous” heart surgery.
This innovation spawned a company, Edwards Laboratories, which set up shop in Santa Ana, California – not far from where Edwards Lifesciences’ corporate headquarters is located today.
In 1966, Edwards Laboratories was purchased by American Hospital Supply Corporation and became American Edwards Laboratories. Then, in 1985, American Edwards was acquired by Baxter International Inc. In early 2000, the company was spun off as an independent, publicly held corporation and began trading on the New York Stock Exchange under the symbol “EW.”
Today, Edwards continues as a leader in the field of tissue replacement heart valves and repair products and advanced hemodynamic monitoring, which have helped treat and manage more than 2 million patients worldwide. Each year, more than 300,000 valve replacements are performed worldwide through open-heart surgery, utilizing either bioprosthetic tissue valves or mechanical valves. Edwards products include tissue replacement heart valves, sold under such brand names as Carpentier-Edwards PERIMOUNT and Carpentier-Edwards PERIMOUNT MAGNA, and also valve repair products that are used by surgeons to fix, instead of replace, a patient’s valve.
The Edwards SAPIEN family of heart valves are delivered via a procedure called transcatheter aortic valve replacement (TAVR). This procedure enables the placement of a collapsible heart valve into the body via a tube-based delivery system (catheter) that can be inserted through multiple access routes, including either an incision in the leg (transfemoral), or in between the ribs and to be threaded up to the heart (transapical), or through the front of the chest and then through a small hole in the aorta (transaortic). The valve is designed to replace a patient’s diseased native aortic valve without traditional open-heart surgery and while the heart continues to beat – avoiding the need to stop the patient’s heart and connect them to a heart-lung machine that temporarily takes over the function of the heart and the patient’s breathing during surgery (cardiopulmonary bypass).
Edwards also manufactures products for vascular therapy along with hemodynamic monitoring devices for measuring cardiovascular performance during surgery and in the ICU. Hemodynamic monitoring is the measurement of blood circulation and cardiac function that allows clinicians to evaluate whether enough oxygen is being delivered to the organs and tissues. Among these is the Swan-Ganz catheter. Originally developed for patients with acute myocardial infarction, it is now used in anesthesia and critical care units. Healthcare providers use this monitoring to detect changes or problems in a patient’s health, which allows for more informed, immediate treatment decisions.
To facilitate on-pump cardiac surgery procedures through smaller incisions, Edwards also offers a cardiac surgery product line comprising soft tissue retractors, venous and arterial cannulae, aortic occlusion, venting, and coronary sinus catheters, as well as reusable instruments for performing minimally invasive valvular procedures.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2022 | 2023-04-26 | Future report Set alerts | |
Q3 2022 | 2022-10-27 | 0.61 | 0.61 |
Q2 2022 | 2022-07-28 | 0.63 | 0.63 |
Q1 2022 | 2022-04-26 | 0.60 | 0.60 |
Q4 2021 | 2022-01-26 | 0.51 | 0.51 |
Q3 2021 | 2021-10-27 | 0.54 | 0.54 |
Q2 2021 | 2021-07-29 | 0.64 | 0.64 |
Q1 2021 | 2021-04-20 | 0.54 | 0.54 |
Q4 2020 | 2021-01-27 | 0.50 | 0.50 |
Q3 2020 | 2020-10-21 | 0.51 | 0.51 |
2016-07-12 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
2016-06-21 | Reiterated Rating | Piper Jaffray | Overweight | $123.00 |
2016-06-21 | Reiterated Rating | William Blair | Outperform | |
2016-06-21 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $123.00 |
2016-06-08 | Reiterated Rating | Credit Suisse | Buy | |
2016-06-08 | Initiated Coverage | Guggenheim | Neutral | |
2016-06-08 | Reiterated Rating | Credit Suisse Group AG | Buy | |
2016-06-01 | Reiterated Rating | JMP Securities | Mkt Perform | |
2016-06-01 | Reiterated Rating | Canaccord Genuity | Buy | $132.00 |
2016-05-25 | Reiterated Rating | Piper Jaffray | Overweight | $123.00 |
2016-05-23 | Boost Price Target | Canaccord Genuity | Buy | $123.00 to $132.00 |
2016-04-28 | Reiterated Rating | Piper Jaffray | Overweight | $97.00 to $123.00 |
2016-04-27 | Reiterated Rating | Jefferies Group | Buy | $105.00 to $125.00 |
2016-04-27 | Reiterated Rating | BMO Capital Markets | Buy | |
2016-04-27 | Reiterated Rating | Morgan Stanley | Buy | |
2016-04-27 | Reiterated Rating | Leerink Swann | Buy | $115.00 to $125.00 |
2016-04-27 | Boost Price Target | Canaccord Genuity | Buy | $113.00 to $123.00 |
2016-04-27 | Reiterated Rating | RBC Capital | Outperform | $110.00 to $125.00 |
2016-04-27 | Reiterated Rating | Cowen and Company | Outperform | $105.00 to $120.00 |
2016-04-27 | Reiterated Rating | Citigroup Inc. | Sell | $67.00 to $86.00 |
2016-04-27 | Reiterated Rating | Royal Bank Of Canada | Outperform | $110.00 to $125.00 |
2016-04-11 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $110.00 to $120.00 |
2016-04-08 | Boost Price Target | Goldman Sachs | $100.00 to $125.00 | |
2016-04-08 | Boost Price Target | Goldman Sachs Group Inc. | $100.00 to $125.00 | |
2016-04-07 | Lower Price Target | Barclays | Equal Weight | $105.00 to $87.00 |
2016-04-07 | Lower Price Target | Barclays PLC | Equal Weight | $105.00 to $87.00 |
2016-04-06 | Reiterated Rating | Morgan Stanley | Buy | |
2016-04-06 | Reiterated Rating | Bank of America | Hold | $102.00 |
2016-04-06 | Reiterated Rating | Bank of America Corp. | Hold | $102.00 |
2016-04-05 | Downgrade | Northland Securities | Outperform to Market Perform | $105.00 |
2016-04-04 | Boost Price Target | Canaccord Genuity | Buy | $95.00 to $113.00 |
2016-04-04 | Lower Price Target | BMO Capital Markets | Outperform | $114.00 to $93.00 |
2016-04-04 | Lower Price Target | Leerink Swann | Outperform | $115.00 to $93.00 |
2016-04-04 | Boost Price Target | Jefferies Group | Buy | $100.00 to $105.00 |
2016-04-04 | Upgrade | BTIG Research | Neutral to Buy | $115.00 |
2016-04-04 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $98.00 to $110.00 |
2016-04-04 | Boost Price Target | Credit Suisse | Outperform | $88.00 to $98.00 |
2016-04-04 | Lower Price Target | Stifel Nicolaus | Buy | $117.00 to $98.00 |
2016-04-04 | Boost Price Target | RBC Capital | Outperform | $100.00 to $110.00 |
2016-04-04 | Reiterated Rating | Wells Fargo | Buy | |
2016-04-04 | Reiterated Rating | Barclays | Hold | $87.00 |
2016-04-04 | Reiterated Rating | Wells Fargo & Co. | Buy | |
2016-04-02 | Upgrade | BTIG Research | Neutral to Buy | $115.00 |
2016-03-24 | Reiterated Rating | Jefferies Group | Buy | $100.00 |
2016-03-17 | Initiated Coverage | Nomura | Buy | $101.00 |
2016-03-17 | Initiated Coverage | Nomura Holdings Inc. | Buy | $101.00 |
2016-03-08 | Reiterated Rating | SunTrust | Buy | |
2016-03-08 | Reiterated Rating | SunTrust Banks Inc. | Buy | |
2016-03-07 | Lower Price Target | SunTrust | Neutral | $100.00 to $88.00 |
2016-02-26 | Reiterated Rating | Citigroup Inc. | Sell | $67.00 |
2016-02-18 | Boost Price Target | Canaccord Genuity | Buy | $92.00 to $95.00 |
2016-02-03 | Reiterated Rating | Piper Jaffray | Buy | $90.00 to $97.00 |
2016-02-03 | Reiterated Rating | Wells Fargo | Buy | |
2016-02-03 | Reiterated Rating | Credit Suisse | Buy | $88.00 |
2016-02-03 | Boost Price Target | Goldman Sachs | Buy | $91.00 to $96.00 |
2016-02-03 | Reiterated Rating | BMO Capital Markets | Buy | $93.00 |
2016-02-03 | Reiterated Rating | Barclays | Equal Weight | $85.00 to $87.00 |
2016-02-03 | Reiterated Rating | Canaccord Genuity | Buy | $90.00 to $92.00 |
2016-02-03 | Lower Price Target | RBC Capital | Outperform | $100.00 to $93.00 |
2016-01-21 | Reiterated Rating | Leerink Swann | Outperform | $93.00 |
2016-01-21 | Upgrade | SunTrust | Neutral to Buy | $86.00 to $88.00 |
2016-01-07 | Initiated Coverage | SunTrust | Neutral | $86.00 |
2016-01-06 | Initiated Coverage | JMP Securities | Market Perform | |
2016-01-05 | Initiated Coverage | Evercore ISI | Hold | $84.50 |
2016-01-04 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
2016-01-04 | Boost Price Target | Sterne Agee CRT | Buy | $90.00 to $92.00 |
2015-12-29 | Reiterated Rating | Credit Suisse | Buy | |
2015-12-29 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $84.00 to $98.00 |
2015-12-23 | Reiterated Rating | Credit Suisse | Outperform | $81.00 to $88.00 |
2015-12-17 | Boost Price Target | Jefferies Group | Buy | $90.00 to $100.00 |
2015-12-15 | Reiterated Rating | BTIG Research | Hold | |
2015-12-10 | Reiterated Rating | Canaccord Genuity | Buy | |
2015-12-10 | Boost Price Target | Stifel Nicolaus | Buy | $89.50 to $97.50 |
2015-12-10 | Lower Price Target | Cowen and Company | Outperform | $92.50 to $46.50 |
2015-12-09 | Reiterated Rating | BTIG Research | Neutral | |
2015-11-13 | Boost Price Target | Goldman Sachs | $83.50 to $88.00 | |
2015-11-12 | Initiated Coverage | Citigroup Inc. | Sell | $67.00 |
2015-10-27 | Boost Price Target | BMO Capital Markets | Outperform | $85.00 to $86.50 |
2015-10-27 | Boost Price Target | Barclays | Equal Weight | $77.50 to $80.00 |
2015-10-26 | Reiterated Rating | Canaccord Genuity | Buy | $89.00 |
2015-10-19 | Upgrade | Wells Fargo | Priority List | |
2015-10-16 | Reiterated Rating | Canaccord Genuity | Buy | $89.00 |
2015-10-09 | Initiated Coverage | Cowen and Company | Outperform | $92.50 |
2015-09-28 | Reiterated Rating | RBC Capital | Outperform | $92.50 |
2015-08-28 | Reiterated Rating | Jefferies Group | Buy | $90.00 |
2015-08-27 | Lower Price Target | Goldman Sachs | $84.00 to $83.50 | |
2015-08-10 | Reiterated Rating | Credit Suisse | Buy | $75.00 to $81.00 |
2015-07-30 | Reiterated Rating | Piper Jaffray | Overweight | $85.00 to $90.50 |
2015-07-29 | Reiterated Rating | Canaccord Genuity | Buy | $89.00 |
2015-07-29 | Reiterated Rating | BTIG Research | Neutral | |
2015-07-29 | Boost Price Target | Barclays | Equal Weight | $75.00 to $77.50 |
2015-07-29 | Boost Price Target | Stifel Nicolaus | Buy | $78.50 to $89.50 |
2015-07-13 | Reiterated Rating | BMO Capital Markets | Buy | $79.00 to $83.50 |
2015-07-13 | Reiterated Rating | BTIG Research | Hold | |
2015-07-13 | Upgrade | Northland Securities | Market Perform to Outperform | $70.00 to $85.00 |
2015-07-13 | Upgrade | RBC Capital | Sector Perform to Outperform | $67.50 to $92.50 |
2015-07-06 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $67.50 to $84.00 |
2015-06-18 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 |
2015-06-09 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $79.00 |
2015-05-19 | Set Price Target | Canaccord Genuity | Buy | $80.00 |
2015-05-12 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $73.50 to $77.50 |
2015-04-27 | Boost Price Target | Deutsche Bank | Hold | $66.50 to $70.00 |
2015-04-27 | Boost Price Target | Deutsche Bank AG | Hold | $66.50 to $70.00 |
2015-04-26 | Reiterated Rating | BTIG Research | Neutral | |
2015-04-26 | Reiterated Rating | Canaccord Genuity | Buy | $80.00 |
2015-04-24 | Boost Price Target | Barclays | Equal Weight | $70.00 to $75.00 |
2015-03-12 | Reiterated Rating | Canaccord Genuity | Buy | $79.50 |
2015-03-09 | Boost Price Target | Barclays | Equal Weight | $58.50 to $65.00 |
2015-02-04 | Reiterated Rating | BTIG Research | Hold | |
2015-02-04 | Set Price Target | Canaccord Genuity | Buy | $79.50 |
2015-02-04 | Boost Price Target | RBC Capital | Sector Perform | $57.50 to $62.50 |
2015-01-06 | Downgrade | Northland Securities | Outperform to Market Perform | $70.00 |
2014-12-09 | Reiterated | Northland Capital | Outperform | $130 to $140 |
2014-12-09 | Boost Price Target | Canaccord Genuity | Buy | $76.50 to $79.50 |
2014-12-09 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $60.00 to $62.00 |
2014-12-09 | Boost Price Target | Deutsche Bank | Hold | $57.50 to $66.50 |
2014-12-09 | Boost Price Target | Barclays | Equal Weight | $46.00 to $50.00 |
2014-12-09 | Boost Price Target | Jefferies Group | Buy | $60.50 to $77.50 |
2014-12-09 | Boost Price Target | Morgan Stanley | Equal Weight | $60.00 to $65.00 |
2014-12-09 | Reiterated Rating | Bank of America | Neutral | $60.00 to $70.00 |
2014-12-09 | Boost Price Target | Stifel Nicolaus | Buy | $66.00 to $72.00 |
2014-12-09 | Boost Price Target | Northland Securities | Outperform | $65.00 to $70.00 |
2014-12-08 | Boost Price Target | Credit Suisse | Outperform | $57.50 to $75.00 |
2014-12-04 | Initiated Coverage | Sanford C. Bernstein | Outperform | $77.50 |
2014-11-07 | Downgrade | Sterne Agee CRT | Buy to Neutral | $58.00 |
2014-10-24 | Reiterated | Northland Capital | Outperform | $100 to $130 |
2014-10-24 | Reiterated Rating | CRT Capital | Buy | $50.00 to $62.50 |
2014-10-24 | Boost Price Target | Stifel Nicolaus | Buy | $50.00 to $66.00 |
2014-10-24 | Reiterated Rating | Morgan Stanley | Equal Weight | $57.50 to $60.00 |
2014-10-24 | Boost Price Target | Northland Securities | Outperform | $50.00 to $65.00 |
2014-09-25 | Boost Price Target | Piper Jaffray | Overweight | $47.50 to $60.00 |
2014-09-16 | Boost Price Target | Canaccord Genuity | Buy to Buy | $51.50 to $57.00 |
2014-09-10 | Initiated Coverage | Sterne Agee CRT | Buy | $55.00 |
2014-08-21 | Boost Price Target | JMP Securities | Outperform | $48.50 to $60.00 |
2014-07-31 | Boost Price Target | Stifel Nicolaus | $45.00 to $50.00 | |
2014-07-31 | Boost Price Target | JPMorgan Chase & Co. | $39.00 to $45.00 | |
2014-07-31 | Boost Price Target | CRT Capital | $45.00 to $50.00 | |
2014-07-31 | Boost Price Target | BMO Capital Markets | $42.00 to $44.50 | |
2014-07-30 | Reiterated | Northland Capital | Outperform | $90 to $100 |
2014-07-30 | Boost Price Target | Canaccord Genuity | Buy | $48.00 to $51.50 |
2014-07-30 | Reiterated Rating | Deutsche Bank | Hold | $40.50 to $45.00 |
2014-07-30 | Reiterated Rating | Barclays | Equal Weight | $33.50 to $36.50 |
2014-07-30 | Boost Price Target | Northland Securities | Outperform | $45.00 to $50.00 |
2014-07-30 | Boost Price Target | Jefferies Group | Buy | $47.00 to $50.00 |
2014-07-29 | Boost Price Target | RBC Capital | Sector Perform | $35.00 to $39.50 |
2014-06-11 | Upgrade | JMP Securities | Market Perform to Outperform | $48.50 |
2014-05-22 | Boost Price Target | CRT Capital | Buy | $43.50 to $45.00 |
2014-05-21 | Boost Price Target | Canaccord Genuity | Buy | $43.00 to $48.00 |
2014-05-09 | Boost Price Target | Leerink Swann | $45.00 to $46.50 | |
2014-04-25 | Boost Price Target | Jefferies Group | $47.00 | |
2014-04-25 | Boost Price Target | Canaccord Genuity | Buy | $42.00 to $43.00 |
2014-04-25 | Reiterated Rating | Stifel Nicolaus | Buy | $37.50 to $45.00 |
2014-04-14 | Upgrade | CRT Capital | Fair Value to Buy | $39.50 to $43.50 |
2014-04-14 | Boost Price Target | Deutsche Bank | $31.00 to $39.00 | |
2014-04-14 | Upgrade | Wells Fargo & Co. | Neutral to Buy | $82.97 to $90.00 |
2014-04-14 | Upgrade | JPMorgan Chase & Co. | Underweight to Neutral | $30.00 to $39.00 |
2014-04-14 | Reiterated Rating | Bank of America | Hold | $42.50 |
2014-04-14 | Boost Price Target | Barclays | Equal Weight | $32.00 to $33.50 |
2014-04-14 | Upgrade | Wells Fargo | Neutral to Buy | $41.49 to $45.00 |
2014-03-31 | Boost Price Target | BMO Capital Markets | $31.50 to $33.00 | |
2014-03-24 | Reiterated Rating | Bank of America | Neutral | $33.50 |
2014-03-10 | Upgrade | Wells Fargo & Co. | Market Perform to Outperform | |
2014-03-10 | Upgrade | Wells Fargo | Market Perform to Outperform | |
2014-03-07 | Boost Price Target | CRT Capital | Fair Value | $36.00 to $39.50 |
2014-03-06 | Boost Price Target | Northland Securities | $45.00 | |
2014-02-20 | Initiated Coverage | BTIG Research | Neutral | |
2014-01-28 | Boost Price Target | Leerink Swann | $36.00 to $40.00 | |
2014-01-14 | Boost Price Target | Canaccord Genuity | $37.00 to $39.00 | |
2013-12-10 | Lower Price Target | Barclays | Equal Weight | $68.00 to $64.00 |
2013-12-10 | Reiterated Rating | Citigroup Inc. | Buy | $75.00 to $72.00 |
2013-12-10 | Reiterated Rating | Canaccord Genuity | Buy | $76.00 to $74.00 |
2013-12-10 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
2013-12-10 | Downgrade | Wells Fargo | Outperform to Market Perform | |
2013-11-26 | Initiated Coverage | CRT Capital | Fair Value | $72.00 |
2013-11-04 | Lower Price Target | Deutsche Bank | Hold | $73.00 to $61.00 |
2013-10-30 | Lower Price Target | RBC Capital | Sector Perform | $75.00 to $60.00 |
2013-10-30 | Boost Price Target | Northland Securities | Outperform | $74.00 to $80.00 |
2013-10-30 | Lower Price Target | Barclays | Equal Weight | $72.00 to $68.00 |
2013-10-30 | Lower Price Target | Jefferies Group | Buy | $85.00 to $80.00 |
2013-10-30 | Lower Price Target | Canaccord Genuity | Buy | $94.00 to $76.00 |
2013-10-30 | Downgrade | JPMorgan Chase & Co. | Neutral to Underweight | $64.00 to $62.00 |
2013-10-29 | Boost Price Target | BMO Capital Markets | Market Perform | $69.00 to $73.00 |
2013-10-29 | Reiterated Rating | RBC Capital | Hold | $75.00 |
2013-10-29 | Boost Price Target | Canaccord Genuity | Buy | $90.00 to $94.00 |
2013-10-16 | Upgrade | Citigroup Inc. | Neutral to Buy | $75.00 to $86.00 |
2013-10-03 | Reiterated | Stifel | Buy | $81 to $82 |
2013-10-03 | Reiterated Rating | RBC Capital | Hold | $75.00 |
2013-10-03 | Boost Price Target | Stifel Nicolaus | Buy | $81.00 to $82.00 |
2013-07-18 | Upgrade | Northland Capital | Market Perform to Outperform | $74 |
2016-07-12 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
2016-06-21 | Reiterated Rating | Piper Jaffray | Overweight | $123.00 |
2016-06-21 | Reiterated Rating | William Blair | Outperform | |
2016-06-21 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $123.00 |
2016-06-08 | Reiterated Rating | Credit Suisse | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In EW 794 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 52.40M |
Vanguard Group, Inc | 50.91M |
STATE STREET CORP | 26.81M |
Capital International Investors | 22.70M |
ALLIANCEBERNSTEIN L.P. | 17.16M |
WELLINGTON MANAGEMENT CO LLP | 14.65M |
BROWN ADVISORY INC | 14.23M |
GEODE CAPITAL MANAGEMENT, LLC | 11.93M |
SANDS CAPITAL MANAGEMENT, LLC | 10.41M |
Fisher Asset Management, LLC | 7.54M |
HENDERSON GROUP PLC | 7.40M |
FMR LLC | 6.62M |
NORTHERN TRUST CORP | 6.50M |
MORGAN STANLEY | 6.33M |
BlackRock Institutional Trust Company, N.A. | 5.68M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Verguet Patrick B CVP, Europe | 0.12% (129137) | EW / |
Wood Larry L CVP, THV Replacement | 0.10% (110001) | EW / |
Cardis John T | 0.09% (91458) | AVY / EW / |
BOWLIN MICHAEL R | 0.08% (81751) | EW / FTI / |
WANG HUIMIN CVP, Japan & Intercontinental | 0.08% (81215) | EW / |
GARREN BRUCE P CVP, Public Affairs/Special Co | 0.05% (56071) | EW / |
PYOTT DAVID E I | 0.05% (53582) | AGN / ALNY / AVY / BMRN / EW / |
MCNEIL BARBARA J | 0.04% (46454) | EW / |
Abate Thomas M CVP, CFO | 0.04% (43047) | EW / |
MUSSALLEM MICHAEL A Chairman & CEO | 0.04% (41330) | EW / |
Lemercier Jean-Luc M CVP, EMEA, Canada, Latin Amer | 0.04% (38840) | EW / |
VON SCHACK WESLEY W | 0.04% (37306) | BK / EW / TDY / |
INGRAM ROBERT ALEXANDER | 0.03% (32367) | BCRX / CREE / EW / REGN / VRX / |
Szyman Catherine M CVP, Critical Care & Vascular | 0.03% (31773) | EW / MDT / |
Solomon Carlyn D CVP, Critical Care & Vascular | 0.03% (31154) | EW / HRC / |
BOBO DONALD E JR CVP, Heart Valve Therapy | 0.02% (19767) | EW / |
LINK WILLIAM J PHD | 0.02% (16000) | EW / INGN / |
SELLERS ROBERT W.A. VP, Corporate Controller | 0.01% (13092) | EW / |
Zovighian Bernard J CVP, Surgical Heart Valves | 0.01% (12588) | EW / |
Redmond Paul C CVP, Global Operations | 0.01% (12534) | EW / |
Ullem Scott B. CVP, CFO | 0.01% (10968) | BERY / BMS / EW / |
Gallahue Kieran | 0.01% (9042) | CFN / EW / VOLC / |
VALERIANI NICHOLAS J | 0.01% (7017) | EW / ROKA / RTIX / |